galantamine has been researched along with deferoxamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agrawal, M; Alexander, A; Antimisiaris, SG; Chougule, MB; Saraf, S; Shoyele, SA | 1 |
2 review(s) available for galantamine and deferoxamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Blood-Brain Barrier; Brain; Deferoxamine; Donepezil; Drug Carriers; Drug Liberation; Galantamine; Humans; Mucociliary Clearance; Nanoparticles; Nasal Mucosa; Nose; Olfactory Bulb; Risperidone; Tissue Distribution | 2018 |